. Author manuscript; available in PMC: 2012 Dec 1.

Published in final edited form as: Drug Alcohol Depend. 2011 Jun 28;119(1-2):e23–e29. doi: 10.1016/j.drugalcdep.2011.05.019

Table 2.

Summary of Adverse Events reported in greater than 5% of randomized participants.

	Number (%) of participants
	Placebo (N=27)	Memantine 30 mg/d (N=27)	Memantine 60 mg/d (N=27)

Number of Participants who were removed from trial because of SAEs^*	0	1	0
Number of Participants with at least 1 TEAE^*	16	10	17
Number of Participants requiring dose reduction	12	9	12
TEAEs^*
Headache	5 (18.5)	2 (7.41)	3 (11.1)
Insomnia	7 (25.9)	8 (29.6)	9 (33.3)
Body Aches	2 (7.41)	1 (3.7)	2 (7.41)
Dizziness	3 (11.1)	2 (7.41)	2 (7.41)
Nausea/Vomiting	1 (3.7)	1 (3.7)	5 (18.5)
Weakness	1 (3.7)	3 (11.1)	1 (3.7)
Diarrhea	4 (14.8)	2 (7.41)	4 (14.8)
GI Distress	7 (25.9)	0 (0.00)	7 (25.9)

AE, adverse event, SAE, serious adverse event; TEAE, treatment-emergent adverse event. No significant differences were detected between treatment conditions.